Day: March 9, 2026

Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This milestone follows the completion of a clinical trial2 validating the system’s significant potential across multiple dental specialties. The trial highlighted this first-of-its-kind technology’s applicability in endodontics, periodontics, TMJ, tooth extraction, and orthodontics, offering non-ionizing imaging capabilities that can enhance diagnosis and treatment planning. CHARLOTTE, N.C., March 09, 2026 (GLOBE NEWSWIRE) — Dentsply Sirona and Siemens Healthineers are pleased to share key findings from the clinical trial for validation of their dental-dedicated MRI system. In addition to confirming its significant potential...

Ceremony highlights Eagle’s recent public listing and Nasdaq debut under ticker “NUCL” RENO, Nev., March 09, 2026 (GLOBE NEWSWIRE) — Eagle Nuclear Energy Corp. (“Eagle” or the “Company”), a next-generation nuclear energy company which owns the largest conventional, measured and indicated uranium deposit in the United States, today announced that CEO Mark Mukhija will ring the Nasdaq Opening Bell at 9:30 a.m. ET on Wednesday, March 11, in recognition of the Company’s recent public listing. Eagle officially commenced trading on the Nasdaq on February 25, 2025, under the ticker symbols “NUCL”, marking a new chapter as a publicly traded U.S.-focused uranium development company. Eagle is the first domestic uranium resource exploration company with exclusive small modular reactor (SMR) technology to list on a U.S. exchange. Anchored...

March 9, 2026 Biodexa Announces Support for Life’s a Polyp FoundationFirst U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to recognise Life’s a Polyp Foundation on its official launch following an initial financial grant from Biodexa to support the organization’s vital work empowering patients with Familial Adenomatous Polyposis (FAP). The Life’s a Polyp Foundation, led by dedicated FAP advocate Jenny Jones, marks the first U.S.-based patient advocacy group dedicated exclusively to FAP, providing essential resources, community support, and awareness for patients and families facing this rare genetic...

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy  New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today presented encouraging preclinical data evaluating TN-301, the company’s highly selective HDAC6 inhibitor, at the Muscular Dystrophy Association’s...

— The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients with obesity receiving semaglutide — — Interim analysis expected in the first quarter calendar year 2027– — Final topline clinical data expected in the fourth quarter calendar year 2027– MIAMI, FL, March 09, 2026 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that it has enrolled the first patient in its Phase 2b PLATEAU clinical trial of enobosarm, an oral selective androgen receptor modulator (SARM), to preserve muscle and physical...

ROCHESTER, NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) — Syntec Optics (Nasdaq: OPTX), a leading provider of mission-critical technologies for defense tech and other vibrant end-markets, today announced it has secured over $4 million in defense purchase orders.  As global combat environments evolve, Syntec Optics is playing a pivotal role in providing the high-precision optical products required for next-generation battlefield dominance.  These new orders support the previously announced participation in a diverse range of mission-critical platforms for U.S. Defense, including missile guidance, compact lasers, surveillance, targeting, aiming, night-vision, and mixed-reality (XR/AR) situational awareness. The new orders for a wide range of platforms reinforce Syntec’s position as a key supplier for high-profile defense initiatives. Syntec...

Agreement Provides for Sale and Promotion of Private Communications Solutions in Ecuador Tel Aviv, Israel, March 09, 2026 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data‑driven company expanding into the global homeland security sector through advanced artificial intelligence (“AI”)‑driven solutions, today announced that its wholly‑owned subsidiary, KeepZone AI Inc. (“KeepZone”), has entered into a channel partner agreement (the “Agreement”) with TDCOMM Ltd. (“TDCOMM”) , a provider of next‑generation private LTE and 5G wireless network solutions. Under the terms of the Agreement, KeepZone has been appointed as a distributor for TDCOMM’s private wireless network solutions in Ecuador,  with the ability to expand into additional territories on a case-by-case basis upon mutual...